163 related articles for article (PubMed ID: 30894378)
1. Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells.
Di Lorenzo B; Simões AE; Caiado F; Tieppo P; Correia DV; Carvalho T; da Silva MG; Déchanet-Merville J; Schumacher TN; Prinz I; Norell H; Ravens S; Vermijlen D; Silva-Santos B
Cancer Immunol Res; 2019 Apr; 7(4):552-558. PubMed ID: 30894378
[TBL] [Abstract][Full Text] [Related]
2. CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells.
Mensurado S; Condeço C; Sánchez-Martínez D; Shirley S; Coelho RML; Tirado N; Vinyoles M; Blanco-Domínguez R; Barros L; Galvão B; Custódio N; Gomes da Silva M; Menéndez P; Silva-Santos B
Blood; 2024 Apr; 143(15):1488-1495. PubMed ID: 38437507
[TBL] [Abstract][Full Text] [Related]
3. The CD226-ERK1/2-LAMP1 pathway is an important mechanism for Vγ9Vδ2 T cell cytotoxicity against chemotherapy-resistant acute myeloid leukemia blasts and leukemia stem cells.
Wu K; Wang LM; Liu M; Xiu Y; Hu Y; Fu S; Huang H; Xu B; Xiao H
Cancer Sci; 2021 Aug; 112(8):3233-3242. PubMed ID: 34107135
[TBL] [Abstract][Full Text] [Related]
4. Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion/Differentiation and Preclinical Proof of Concept.
Almeida AR; Correia DV; Fernandes-Platzgummer A; da Silva CL; da Silva MG; Anjos DR; Silva-Santos B
Clin Cancer Res; 2016 Dec; 22(23):5795-5804. PubMed ID: 27307596
[TBL] [Abstract][Full Text] [Related]
5. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model.
Ma Q; Wang C; Jones D; Quintanilla KE; Li D; Wang Y; Wieder ED; Clise-Dwyer K; Alatrash G; Mj Y; Munsell MF; Lu S; Qazilbash MH; Molldrem JJ
Cytotherapy; 2010 Dec; 12(8):1056-62. PubMed ID: 20735170
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
O'Hear C; Heiber JF; Schubert I; Fey G; Geiger TL
Haematologica; 2015 Mar; 100(3):336-44. PubMed ID: 25480499
[TBL] [Abstract][Full Text] [Related]
7. Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.
Distler E; Albrecht J; Brunk A; Khan S; Schnürer E; Frey M; Mottok A; Jordán-Garrote AL; Brede C; Beilhack A; Mades A; Tomsitz D; Theobald M; Herr W; Hartwig UF
Int J Cancer; 2016 Mar; 138(5):1256-68. PubMed ID: 26376181
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.
Distler E; Wölfel C; Köhler S; Nonn M; Kaus N; Schnürer E; Meyer RG; Wehler TC; Huber C; Wölfel T; Hartwig UF; Herr W
Exp Hematol; 2008 Apr; 36(4):451-63. PubMed ID: 18261837
[TBL] [Abstract][Full Text] [Related]
9. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
10. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
Zhou L; Liu X; Wang X; Sun Z; Song XT
Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
[TBL] [Abstract][Full Text] [Related]
11. Selection of Tumor-Specific Cytotoxic T Lymphocytes in Acute Myeloid Leukemia Patients Through the Identification of T-Cells Capable to Establish Stable Interactions With the Leukemic Cells: "Doublet Technology".
García-Guerrero E; Sánchez-Abarca LI; Domingo E; Ramos TL; Bejarano-García JA; Gonzalez-Campos JA; Caballero-Velázquez T; Pérez-Simón JA
Front Immunol; 2018; 9():1971. PubMed ID: 30233577
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms.
Lee J; Minden MD; Chen WC; Streck E; Chen B; Kang H; Arruda A; Ly D; Der SD; Kang S; Achita P; D'Souza C; Li Y; Childs RW; Dick JE; Zhang L
Clin Cancer Res; 2018 Jan; 24(2):370-382. PubMed ID: 29074605
[No Abstract] [Full Text] [Related]
13. A modular and controllable T cell therapy platform for acute myeloid leukemia.
Benmebarek MR; Cadilha BL; Herrmann M; Lesch S; Schmitt S; Stoiber S; Darwich A; Augsberger C; Brauchle B; Rohrbacher L; Oner A; Seifert M; Schwerdtfeger M; Gottschlich A; Rataj F; Fenn NC; Klein C; Subklewe M; Endres S; Hopfner KP; Kobold S
Leukemia; 2021 Aug; 35(8):2243-2257. PubMed ID: 33414484
[TBL] [Abstract][Full Text] [Related]
14. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.
Zhou Q; Bucher C; Munger ME; Highfill SL; Tolar J; Munn DH; Levine BL; Riddle M; June CH; Vallera DA; Weigel BJ; Blazar BR
Blood; 2009 Oct; 114(18):3793-802. PubMed ID: 19724059
[TBL] [Abstract][Full Text] [Related]
15. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
Bonifant CL; Szoor A; Torres D; Joseph N; Velasquez MP; Iwahori K; Gaikwad A; Nguyen P; Arber C; Song XT; Redell M; Gottschalk S
Mol Ther; 2016 Sep; 24(9):1615-26. PubMed ID: 27401038
[TBL] [Abstract][Full Text] [Related]
16. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
[TBL] [Abstract][Full Text] [Related]
17. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
18. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.
van der Lee DI; Reijmers RM; Honders MW; Hagedoorn RS; de Jong RC; Kester MG; van der Steen DM; de Ru AH; Kweekel C; Bijen HM; Jedema I; Veelken H; van Veelen PA; Heemskerk MH; Falkenburg JHF; Griffioen M
J Clin Invest; 2019 Feb; 129(2):774-785. PubMed ID: 30640174
[TBL] [Abstract][Full Text] [Related]
19. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia.
Arcangeli S; Rotiroti MC; Bardelli M; Simonelli L; Magnani CF; Biondi A; Biagi E; Tettamanti S; Varani L
Mol Ther; 2017 Aug; 25(8):1933-1945. PubMed ID: 28479045
[TBL] [Abstract][Full Text] [Related]
20. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]